ESMO hears strong data on Novartis' everolimus in kidney cancer and NET tumors
Updated study findings from the RECORD-1 study show that advanced kidney cancer patients on Novartis' RAD001 (everolimus) had no tumor growth for 4.9 months versus 1.9 months for those receiving placebo (p<0.001). In addition, after more than 10 months of treatment, 25% of subjects still had no tumor growth.
According to Bernard Escudier, head of Immunotherapy and Innovative Therapy Unit at the Gustave-Roussy Institute, Paris, France, the results, presented at the 33rd European Society for Medical Oncology Congress in Stockholm, Sweden, should become part of the treatment paradigm for this patient population.
Earlier this year, interim results from RECORD-1 were used to submit regulatory applications for RAD001 as a treatment for metastatic renal cell carcinoma, for which the agent was granted priority review by the US Food and Drug Administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze